Yet, evidence now shows that epigenetic silencing via DNA methylation, deacetylation, and post-translational phosphorylation can downregulate key members like SLFN11 and SLFN12, driving chemoresistance and poor outcomes in cancers such as gastric, colorectal, and ovarian tumors [18,19,20]. This evidence concerns the gene SLFN12 and cancer.